Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Alibaba Group (BABA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Alibaba Group — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.08 (market cap $39.89B), while Alibaba Group trades at $113.27 (market cap $269.48B). The key difference: Alibaba Group is far larger — about 6.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Alibaba Group pays a 0.93% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BABA | |
|---|---|---|
Market Cap | $39.89B | $269.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $189.34 |
52-Week Low | $278.09 | $94.83 |
Enterprise Value | $38.15B | $264.31B |
Volume | — | 18,069,938 |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Alibaba (BABA) trades at $112.33, up 1.07% today, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with improving fundamentals, including a 13.05% net margin and $130.11B net income for 2025. The stock faces headwinds from securities investigations but benefits from AI momentum and narrowing losses in quick commerce.
Outlook remains positive with an 86% buy rating and $195 consensus target, though risks include regulatory scrutiny and earnings volatility. Upside potential hinges on execution in cloud and e-commerce, while legal overhangs and macroeconomic pressures pose near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →
